Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers

被引：0
|
作者：
Payne, Susan
Foley, Tyler
Pasch, Cheri
Yueh, Alexander
Korkos, Demetra
Van De Hey, Dana
Clipson, Linda
Deming, Dustin
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
618
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
    Foley, Tyler M.
    Payne, Susan N.
    Pasch, Cheri A.
    Yueh, Alex E.
    Van De Hey, Dana R.
    Korkos, Demetra P.
    Clipson, Linda
    Maher, Molly E.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Deming, Dustin A.
    [J]. MOLECULAR CANCER RESEARCH, 2017, 15 (03) : 317 - 327
  • [3] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [4] Dual PI3K/BCL-2 family inhibition in colorectal cancers with Apc and Pik3camutations
    Miller, Devon D.
    Babiarz, Christopher P.
    Payne, Susan N.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Deming, Dustin A.
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [5] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    [J]. CANCER RESEARCH, 2016, 76
  • [6] PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
    Janku, Filip
    Tsimberidou, Apostolia M.
    Garrido-Laguna, Ignacio
    Wang, Xuemei
    Luthra, Rajyalakshmi
    Hong, David S.
    Naing, Aung
    Falchook, Gerald S.
    Moroney, John W.
    Piha-Paul, Sarina A.
    Wheler, Jennifer J.
    Moulder, Stacy L.
    Fu, Siqing
    Kurzrock, Razelle
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (03) : 558 - 565
  • [7] PIK3CA Mutations PREDICT RESPONSE TO PI3K/AKT/mTOR INHIBITORS
    不详
    [J]. CANCER DISCOVERY, 2012, 2 (03) : 205 - 205
  • [8] Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
    Kim, Areumnuri
    Lee, Jung-Eun
    Lee, Seung-Sook
    Kim, Cherin
    Lee, Sun-Joo
    Jang, Won-Suk
    Park, Sunhoo
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) : 984 - 996
  • [9] In silico approach to target PI3K/Akt/mTOR axis by selected Olea europaea phenols in PIK3CA mutant colorectal cancer
    Sain, Arindam
    Kandasamy, Thirukumaran
    Naskar, Debdut
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (21): : 10962 - 10977
  • [10] Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
    Moore, Gillian
    Elbai, Samira
    Heavey, Susan
    Finn, Stephen
    O'Neill, Michael
    Gately, Kathy
    [J]. MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 48 - 48
12345